[HTML][HTML] Selective targeting of human alloresponsive CD8+ effector memory T cells based on CD2 expression
DJ Lo, TA Weaver, L Stempora, AK Mehta… - American Journal of …, 2011 - Elsevier
Costimulation blockade (CoB), specifically CD28/B7 inhibition with belatacept, is an
emerging clinical replacement for calcineurin inhibitor-based immunosuppression in
allotransplantation. However, there is accumulating evidence that belatacept incompletely
controls alloreactive T cells that lose CD28 expression during terminal differentiation. We
have recently shown that the CD2-specific fusion protein alefacept controls costimulation
blockade-resistant allograft rejection in nonhuman primates. Here, we have investigated the …
emerging clinical replacement for calcineurin inhibitor-based immunosuppression in
allotransplantation. However, there is accumulating evidence that belatacept incompletely
controls alloreactive T cells that lose CD28 expression during terminal differentiation. We
have recently shown that the CD2-specific fusion protein alefacept controls costimulation
blockade-resistant allograft rejection in nonhuman primates. Here, we have investigated the …
